🔗 Share this article

Given that the US proceeds with historic adjustments to its immunization schedules, a particular individual appears unexpectedly: Høeg, a US-based physician and public health researcher who initially gained attention by casting doubt on coronavirus shots during the pandemic and has focused upon potential fatalities after Covid immunization in her short position at the Food and Drug Administration.

Scheduled Changes to Pediatric Vaccine Program

Public health authorities had intended to reveal sweeping changes to the pediatric vaccine schedule earlier this month, synchronizing the US with Denmark’s vaccine program, it is understood – a substantial departure that would put the US at odds with much of the global community with little proof for benefit. This reveal has been pushed back until the coming year.

Instead of the director of the vaccine center, Tracy Beth Høeg is set to address the audience at the meeting. She was newly appointed acting director of the FDA’s CDER, the fifth appointee to lead the division this calendar year.

A Shift at the FDA

Høeg's temporary position could signify a tighter collaboration between the drug and vaccine divisions as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it points to a renewed priority upon dismantling long-standing vaccines at the FDA.

Høeg has repeatedly called for halting some pediatric vaccine recommendations in the US in order to be more in line with Denmark, a country with universal health coverage and a citizenry approximately the size of Wisconsin’s.

In her initial public appearances, she has continued to focus on vaccination policy – typically the responsibility of Prasad, chief of the FDA’s CBER – rather than drug regulation.

Concerns Over Expertise

Dr. Høeg has no apparent experience in medication creation, oversight or leadership, which has been customary for former directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the commissioner and CBER since March.

“She appears not to have any of the qualifications” for leading the drug-regulation department, stated a neurologist and psychiatrist. “She’s never run a scientific study. She is not versed in managing a sizeable institution. She has no expertise in drug approvals.”

Previous commissioners of CBER would “be deeply familiar with regulatory frameworks and the research of drug development”, said a former acting FDA commissioner. “Clearly, she lacks the type of experience that former directors who ran CBER have had.”

This division has an vast portfolio at the agency, Woodcock emphasized.

“The public just focuses on the innovative therapies, but the off-patent medication office clears thousands of generic drugs. There is also a biosimilars program, over-the-counter program and so forth, and each of these must be supervised,” she said. “The area you neglect, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a major administrative component to the role, which supervises more than 5,000 personnel. “It is a massive management job, if you execute it properly,” she added.

Official Statement and Contentious Initiatives

In response to questions about Høeg’s credentials and whether this appointment represents increased cooperation among agency officials on vaccines, a spokesperson responded that the “questions stem from incorrect assumptions”.

“Her experience aligns with the duties of her position,” the official stated, citing the months Dr. Høeg spent advising the agency head on “drug safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As acting director, Dr. Høeg assumes responsibility for the commissioner’s controversial expedited review system, a controversial expedited drug-approval program that apparently worried her predecessors. “By what process are these drugs being picked for this voucher program? Who takes the calls?” Howard asked. “There is a lot of secrecy occurring at the agency right now.”

In general, he said, “the FDA seems to be moving towards less stringent rules of pharmaceuticals, except for immunizations.”

Documented Past Work on Immunizations

With vaccines, Dr. Høeg has a more documented, if concerning, past, some experts observe. She released a study using unverified volunteer-provided data to estimate the incidence of myocarditis following Covid immunization. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccines are pose a greater threat than they are.

Included in her “desired changes” for the incoming administration encompassed altering regulations for novel immunizations and halting “unnecessary” immunizations, she remarked post-election on a podcast. At the agency, Dr. Høeg has allegedly suggested preventing young men from receiving Covid vaccines.

“She’s an all-around true believer who commences with her preconceived notions and reverse-engineers to retrofit the data in a very deceptive, untruthful way,” Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg aligned with fellow dissenters, {like|